Kalveer Flora, MPharm, London North West University Healthcare National Health Service (NHS) Trust, discusses how the NHS has overcome hurdles related to switching to biosimilars.
Transcript
I think, specific hurdles, and I think we hear this a lot: “Are the biosimilars safe? Are they effective? Are there any side effects?” Having gone through the switches, at each stage, we collected data to show that the biosimilars were just as safe, just as efficacious, worked just as well as the originators.
This mound of evidence helped build confidence at each transition. So our clinicians, our nurses, our pharmacists, our physiotherapists, all of our multidisciplinary team could see that, because we had this wealth of experience, at each stage, they became more confident. So now our consultants wouldn’t even think about having a problem with switching, whereas, in the beginning, we had problems with, “Oh, do they work? What happens if a patient feels that their condition has deteriorated once on it?”
I think, having gone through the process 4 times now, this has helped to build confidence at each level, and now it’s more of a routine thing rather than a new thing.
Stay up to date on the most recent and practice-changing, delivering expert insights, regulatory updates, and clinical trial news on biosimilars.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.